ALKS News and Press, Alkermes plc From 04/09/24

2024-04-09 15:15:03 ET UBS analyst issues BUY recommendation for ALKS on April 9, 2024 01:01PM ET. The previous analyst recommendation was Buy. ALKS was trading at $26.765 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current analyst r...

2024-04-09 13:30:01 ET Jefferies analyst issues BUY recommendation for ALKS on April 9, 2024 12:04PM ET. The previous analyst recommendation was Buy. ALKS was trading at $27 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current analyst...

2024-04-09 13:00:03 ET Akash Tewari from Jefferies issued a price target of $25.00 for ALKS on 2024-04-09 12:04:00. The adjusted price target was set to $25.00. At the time of the announcement, ALKS was trading at $26.95. The overall price target consensus is at $32.00 w...

2024-04-09 09:49:40 ET Summary Alkermes' spinoff transaction with Mural Oncology resulted in cost cutting and higher EBITDA margins, with strong 2023 profitability gains expected to continue into 2024. The stock is currently undervalued compared to peers, but capital allocation in...

2024-04-09 08:59:00 ET U.S. stock index futures on Tuesday pointed to a slightly higher open, a day ahead of a key consumer inflation report. Here are some stocks to watch on Tuesday: ... Read the full article on Seeking Alpha For further details see: 4 stocks to wa...

2024-04-09 08:13:22 ET More on Alkermes Alkermes plc 2023 Q4 - Results - Earnings Call Presentation Alkermes plc (ALKS) Q4 2023 Earnings Call Transcript Alkermes: Additional Narcolepsy Data Could Lead The Way To The Next Stage Baird starts Alkermes at outperf...

Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia PR Newswire — Orexin 2 Receptor Agonist ALKS 2680 Demonstrated Clinically Meaningful and Statist...

Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society PR Newswire DUBLIN , April 8, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today anno...

2024-03-20 14:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-19 14:37:43 ET More on Alkermes Alkermes plc 2023 Q4 - Results - Earnings Call Presentation Alkermes plc (ALKS) Q4 2023 Earnings Call Transcript Alkermes: Additional Narcolepsy Data Could Lead The Way To The Next Stage Alkermes downgraded at UBS as st...